Ten years of experience with the pneumococcal conjugate 7-valent vaccine in children.
Med Mal Infect
; 43(8): 309-21, 2013 Aug.
Article
de En
| MEDLINE
| ID: mdl-23845250
ABSTRACT
In children, pneumococcus became the predominant infectious agent, after the routine use of the Hib conjugate vaccine dramatically decreased Haemophilus Influenzae type b prevalence. The incidence of invasive pneumococcal infections (IPI) and of non-invasive infections due to vaccine serotypes (VS) decreased by 80% in Europe along with a 30-40% decrease in the global incidence of IPI in this age group, after the implementation of Prevenar 7(®) routine immunization in children below 2 years of age. The decrease of IPI due to VS in other age groups was an indirect benefit. The moderate increase of non-vaccinal serotype IPI incidence did not impede the benefit of the overall program. Serotype 19A was the most frequent and carried resistance to antibiotics. Prevenar 13(®), a second-generation vaccine with six new serotypes, replaced Prevenar 7(®) in most countries after 2010, with available evidence of its effectiveness (United Kingdom, US, France).
Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Infections à pneumocoques
/
Vaccins antipneumococciques
Type d'étude:
Incidence_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limites:
Adult
/
Child, preschool
/
Humans
/
Infant
/
Newborn
Pays/Région comme sujet:
America do norte
/
Asia
/
Europa
/
Oceania
Langue:
En
Journal:
Med Mal Infect
Année:
2013
Type de document:
Article
Pays d'affiliation:
France